SEC EDGAR · Company announcement
STLN: Cybersecurity incident
Filed 8-K for an event or period dated 2026-05-20. Cybersecurity incident.
Follow STLN- Became public
- May 22, 2026, 4:30 PM EDT
- Event / period date
- May 20, 2026
- Collected
- Nov 10, 2026, 10:07 AM EST
Why this is connected
This filing identifies Starling Oncology, Inc. as the issuer of the security. The company's SEC identifier connects it to STLN.
Source evidence
Read the source excerpt or record
Item 7.01 of a Current Report on Form 8-K filed on November 6, 2025, regarding a cybersecurity incident affecting a software service provider (“Vendor”) utilized by the Company. At the time of the prior voluntary disclosure, the Vendor had indicated that investigation was still ongoing and it could not yet confirm any evidence that any patient personal information was compromised as a result of this incident. However, on May 20, 2026, Kroll, who is the third-party administrator for the Vendor, notified the Company that the Vendor had detected unauthorized access by a third party to certain information systems of the Company, including systems affecting data of patients. The Company believes that the cybersecurity incident has affected various other healthcare service providers, and the Vendor has set up a patient portal through which it intends to provide information and responses to inquiries. Because of the Company’s technology security and continuity plan, the Company worked swiftly in response, and its operations have continued in all material respects since the detection of the incident. The Company remains committed to protecting the healthcare and other personal information of its patients and will work with the Vendor to offer credit monitoring and protection to all impacted patients. The Company is reserving all rights with respect to potential claims against relevant third parties or service providers. Although the Company’s investigation and assessment remain ongoing, as of the date of this filing, the Company believes that the incident has not had a material impact on the Company’s operations, financial systems, or its quality of care to its patients, and the Company is currently evaluating any other material impact, if any, including on its financial condit
Price change after we could observe it
-10.71% STLN
Adjusted closing prices from Nov 11, 2026 to Nov 12, 2026. SPY changed -0.35% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in STLN
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 26, 2026$1K–$15K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$1K–$15K · Traded Sep 23, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$1K–$15K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$1K–$15K · Traded Sep 23, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$15K–$50K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$15K–$50K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$1K–$15K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$1K–$15K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$15K–$50K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$15K–$50K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$15K–$50K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$15K–$50K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$1K–$15K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$1K–$15K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$15K–$50K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$15K–$50K · Traded Sep 18, 2026 · disclosed Oct 26, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.